All type of patients: 1 trials - ERASE-MI
| elinogrel vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | non cardiovascular death | no data | | Non fatal stroke | 3.18 [0.12 80.77] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | Major bleeding | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
STEMI patients: 2 trials - ERASE-MI - INNOVATE
| elinogrel vs error | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | no data | | non cardiovascular death | no data | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| elinogrel vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | non cardiovascular death | no data | | Non fatal stroke | 3.18 [0.12 80.77] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | Major bleeding | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - ERASE-MI - INNOVATE
| elinogrel vs error | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | no data | | non cardiovascular death | no data | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| elinogrel vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non fatal MI | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | non cardiovascular death | no data | | Non fatal stroke | 3.18 [0.12 80.77] | p=1.00 | 0 | 70 | 1 | ERASE-MI, | | Major bleeding | 1.06 [0.02 54.90] | p=1.00 | 0 | 70 | 1 | ERASE-MI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - INNOVATE PCI
| elinogrel vs clopidogrel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | MACE | no data | | All cause death | no data | | Major bleeding | no data | | net benefit | no data | | stent thrombosis | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
